2Q6-31576-28109
2 vaccinations
1 coded response
14 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 070 / NJ
- Registered
- 2021-03-22
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-06
Dose 1 — Pfizer-BioNTech
-
2021-03-22
Registered in v-safe
- 2021-03-22
- 2021-03-27
-
2021-03-29
Dose 2 — Pfizer-BioNTech
- 2021-03-29
-
2021-03-30
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Chills, Headache, Fatigue or tiredness, Nausea · Be unable to do your normal daily activitiesAdult check-in
- 2021-03-31
- 2021-04-01
- 2021-04-03
- 2021-04-07
- 2021-04-14
- 2021-05-03
- 2021-05-10
- 2021-06-28
- 2021-09-29
-
2022-03-31
Survey response — 12 months, dose 2MedDRA: Nasopharyngitis — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Cold symptomsMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-06 | Pfizer-BioNTech | |
| 2 | 2021-03-29 | Pfizer-BioNTech |
Free text
Release 11 — 12 months, dose 2
Symptoms: Cold symptoms
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Nasopharyngitis | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release